SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints
Both post-implant monotherapies in the trial achieved non-inferiority compared to dual anti-platelet therapy (DAPT) supporting the potential to simplify post-procedure drug regimens MARLBOROUGH, Mass. and SAN DIEGO, Nov. 2, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX)...
Covered in this story
Call it yourself
No calls on $FLX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on BingEx →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.